{"filing":{"accession_number":"0001493152-26-038764","cik":"0002025942","ticker":"CURX","company_name":"Curanex Pharmaceuticals Inc","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-14","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/form8-k.htm"},"events":[{"id":28309,"run_id":25883,"accession_number":"0001493152-26-038764","anchor_item_number":"3.03","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"This disclosure concerns a 1-for-20 reverse stock split approved by the Board and shareholders, effective August 20, 2026, implemented via a Certificate of Amendment to the Articles of Incorporation. The primary purpose stated is to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)). While the reverse split modifies shareholder rights (Item 3.03) and amends the Articles of Incorporation (Item 5.03), it is fundamentally a governance and capital structure action rather than a specific named event type. The materiality is high because the reverse split affects all shareholders' holdings and signals delisting risk mitigation, making it material to investor assessment.","company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30214,"accession_number":"0001493152-26-038764","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure concerns a 1-for-20 reverse stock split approved by the Board and shareholders, effective August 20, 2026, implemented via a Certificate of Amendment to the Articles of Incorporation. The primary purpose stated is to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)). While the reverse split modifies shareholder rights (Item 3.03) and amends the Articles of Incorporation (Item 5.03), it is fundamentally a governance and capital structure action rather than a specific named event type. The materiality is high because the reverse split affects all shareholders' holdings and signals delisting risk mitigation, making it material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:46:37.584584+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30214,"accession_number":"0001493152-26-038764","item_number":"3.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure concerns a 1-for-20 reverse stock split approved by the Board and shareholders, effective August 20, 2026, implemented via a Certificate of Amendment to the Articles of Incorporation. The primary purpose stated is to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)). While the reverse split modifies shareholder rights (Item 3.03) and amends the Articles of Incorporation (Item 5.03), it is fundamentally a governance and capital structure action rather than a specific named event type. The materiality is high because the reverse split affects all shareholders' holdings and signals delisting risk mitigation, making it material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:46:37.584584+00:00","company_name":"Curanex Pharmaceuticals Inc","ticker":"CURX","filing_date":"2026-08-17"}]}